Literature DB >> 8513570

Increased platelet activating factor in the tracheal aspirates from neonates with patent ductus arteriosus.

N Koyama1, Y Ogawa, K Kamiya, H Eguchi, T Tanaka, J Takasaki, Y Ohama, Y Itakura, K Kaneko.   

Abstract

We investigated platelet-activating factor (PAF) in the tracheal aspirate from 3 intubated low birth weight infants with symptomatic patent ductus arteriosus (PDA). PAF increased with the onset of symptomatic PDA and decreased to the control range soon after the ductal closure. The concentration of PAF in 26 samples taken during symptomatic PDA (median 16 pg/micrograms lipid phosphorus, range 1.4-1,200 pg/micrograms lipid phosphorus) was significantly higher than that of 31 samples from the same three patients during the periods without symptomatic PDA (median 1.9 pg/micrograms lipid phosphorus, range 0-12 pg/micrograms lipid phosphorus; P < 0.001). All 3 infants later developed chronic lung disease. These results suggest that large shunting PDA provokes PAF release to the air way of the neonate and that PAF might play a role in chronic lung disease developing after symptomatic PDA.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8513570     DOI: 10.1016/0009-8981(93)90250-8

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  2 in total

1.  Platelet activating factor in surfactant-TA is inhibited by coexisting inhibitors.

Authors:  N Koyama
Journal:  Lung       Date:  2003       Impact factor: 2.584

Review 2.  Management of bronchopulmonary dysplasia in infants: guidelines for corticosteroid use.

Authors:  David G Grier; Henry L Halliday
Journal:  Drugs       Date:  2005       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.